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Patterns and Emerging Mechanisms Review
of the Angiogenic Switch
during Tumorigenesis
Douglas Hanahan* and Judah Folkman†‡ tumors is now well recognized. A considerable body of
research spanning almost three decades has docu-*Department of Biochemistry and Biophysics
Hormone Research Institute mented that tumor growth and metastasis require per-
sistent new blood vessel growth. The classical proof ofUniversity of California, San Francisco
San Francisco, California 94143-0534 this principle came from experiments whereby tumor
fragments or cultured tumor cells were placed in an†Department of Surgery
Children’s Hospital avascular site, the cornea of a rabbit eye (Gimbrone et
al., 1972). The implants attracted new capillaries thatBoston, Massachusetts 02115
‡Depts. of Surgery and Cell Biology grew in from the limbus to vascularize the expanding
tumor mass. If the capillaries were physically preventedHarvard Medical School
Boston, Massachusetts 02115 from reaching the implant or were inhibited from under-
going angiogenesis, tumor growth was dramatically im-
paired, restricting the tumor nodule to a diameter of
approximately 0.4 mm. Subsequent experiments haveIntroduction
confirmed this result and further revealed that in theBlood vessels are fundamentally composed of endothe-
absence of access to an adequate vasculature, tumorlial cells, which interconnect to form the tubes that direct
cells become necrotic (Brem et al., 1976) and/or apop-and maintain blood flow and tissue perfusion. During
totic (Holmgren et al., 1995; Parangi, 1996), restrainingembryogenesis, blood vessels develop via two pro-
the increase in tumor volume that should result fromcesses: vasculogenesis, whereby endothelial cells are
continuous cell proliferation, the hallmark of cancer.born from progenitor cell types; and angiogenesis, in
The principle that ongoing angiogenesis is essentialwhich new capillaries sprout from existing vessels (re-
for rapid expansion of a tumor mass has in turn raisedviewed by Risau, 1995; Risau and Flamme, 1995). In the
another question: when is angiogenesis activated duringadult, new vessels are produced only through angiogen-
the development of a tumor, which invariably takes con-esis. Notably, the vasculature is quiescent in the normal
siderable time and appears to progress along a develop-adult mammal, except for highly orderly processes in
mental pathway composed of distinctive progenitorthe female reproductive cycles (ovulation, menstrua-
stages? Is angiogenesis simply an inevitable conse-tion, implantation, pregnancy). The endothelial cells are
quence whenever nodules of aberrantly proliferatingamong the longest-lived in the body outside the central
cells become size-limited by a lack of vascularization?nervous system; in a normal adult vessel, only 1 in every
Or rather, is controlling the “angiogenic switch” an10,000 endothelial cells (0.01%) is in the cell division
important part of the repertoire of qualities that a de-cycle at any given time (Engerman et al., 1967; Hobson
veloping tumor must acquire to be successful? The evi-and Denekamp, 1984), presumably reflecting a process
dence increasingly points to the latter alternative,of cell turnover to maintain tissue vitality. In contrast,
namely that induction of angiogenesis is a discrete com-about 14% of normal intestinal epithelial cells are in the
ponent of the tumor phenotype, one that is often acti-cell division cycle. Thus, the turnover time to replace
vated during the early, preneoplastic stages in thedevel-the cells of the gut is measured in days and that of the
opment of a tumor. The clues have initially come fromendothelium in years. Yet, in response to an appropriate
transgenic mouse models of cancer and now from cer-stimulus, the quiescent vasculature can become acti-
tain classes of human cancer; in both cases, access tovated to grow new capillaries. This process of angiogen-
tissue containing the stages in tumor development hasesis is complex (reviewed by Auerbach and Auerbach,
been critical to this realization, as is related below.1994; Cockerill et al., 1995; Folkman, 1995a). The base-
ment membrane surrounding the endothelial cell tube
is locally degraded, and the endothelial cells underlying Transgenic Mouse Models Reveal the Angiogenic
Switch in Early Stages of Tumor Developmentthis regional disruption in the barrier change shape and
invade into surrounding stroma. This invasion is accom- Transgenic mice carrying dominant oncogenes and/or
knockouts of tumor suppressor genes are now beingpanied by proliferation of the endothelial cells at the
leading edge of what becomes a migrating column. A widely utilized to study the process of tumorigenesis
(reviewed by Adams and Cory, 1991; Frost et al., 1995;region of differentiation trails behind the advancing
front, where the endothelial cells cease proliferating, Hanahan, 1988, 1989). In a number of these mouse mod-
els, cancers develop through temporally and histologi-change shape, and tightly adhere to each other to form
a lumen of a new capillary tube. Finally, sprouting tubes cally distinct stages, much as is apparent for many hu-
man cancers. The experimental manipulability of thefuse and coalesce into loops, circulating the blood into
this newly vascularized region. Outside of female repro- mouse and the reproducibility afforded by genetic pre-
disposition to specific cancers is allowing the individualductive cycles, angiogenesis in the adult is largely con-
trolled by pathological situations, such as wound heal- stages in tumorigenesis to be studied, and perturbed, in
efforts to establish functional significance of candidateing and tumor growth. The complexity of angiogenesis
implies the existence of multiple controls, some of which genes and cellular processes. Specifically, we and our
colleagues have investigated the pattern of angiogen-are coming into focus, as will be discussed below.
Theimportance of angiogenesis for thegrowth of solid esis in three diverse transgenic mouse models: islet cell
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Figure 1. The Angiogenic Switch Occurs Prior to Tumor Formation in Three Transgenic Mouse Models of Tumorigenesis
(A) Expression of the Tag oncogene in the pancreatic islets elicits four sequential stages in tumor development: normal, oncogene-expressing
islets; hyperplastic islets, populated by proliferating cells with the histological hallmarks of CIS; angiogenic islets, in which new blood vessel
growth has been activated; and solid tumors, which are islet cell carcinomas.
(B) In transgenic mice carrying the BPV-1 oncogenes, the normal dermis is initially converted into a state of mild fibromatosis, revealed as
focal accumulation of dermal fibroblasts. Angiogenesis is first evident in the next stage, aggressive fibromatosis, which is also marked
by dense arrays of proliferating fibroblastic cells; both hyperproliferation and angiogenesis persist in the subsequent stage, protuberant
fibrosarcoma.
(C) Targeted expression of the HPV-16 oncogenes to basal cells of the epidermis induces multistage development of squamous cell carcinoma,
beginning as hyperplasia of keratinocytes, with a mild increase in vessel density; which progresses to dysplasia, marked by morphologically
aberrant keratinocytes with a high proliferation index and by abundant neovascularization; finally, two classes of squamous carcinoma arise,
both evidencing extensive angiogenesis.
carcinoma, dermal fibrosarcoma, and epidermal squa- 12–16 weeks of age. The distribution of this cell type
into thesenatural focal nodules hasallowed histological,mous cell carcinoma. In all three models, extensive vas-
cularization and ongoing angiogenesis has been appar- temporal, and statistical analysis of tumorigenesis. A
set of four discrete stages in the pathway to cancer isent in the end-stage tumors. Remarkably, in each case,
an angiogenic switch could also be visualized during apparent by these criteria. Initially, every islet contains b
cells, which express the oncogene but otherwise appearearly stages preceding the appearance of the solid tu-
mors, suggesting that activation of angiogenesis is a normal, with a low proliferation index. Then, focal activa-
tion of hyperproliferation occurs in individual isletsdiscrete event in tumor development. These models are
summarized briefly, in turn; the results are schematized (Teitelman et al., 1988). This stage, while historically
referred to as “hyperplastic,” is composed of cells within Figure 1.
The so-called “RIP-Tag” transgenic mice express the the histological properties of a carcinoma-in-situ (CIS),
wherein more than 20% of the cells are in S phaseSV40 T antigen (or Tag) oncogene in the insulin-produc-
ing b cells (Hanahan, 1985), which are localized in ap- at any given time. Insulin-like growth factor (IGF)-II is
activated at this stage and probably modulatesproximately 400 islet nodules scattered throughout the
pancreas. In several independent lines of mice, a few apoptosis that accompanies the aberrant proliferation
(Christofori et al., 1994, 1995a; Naik et al., 1994). Yet,(2–10) of these 400 islets develop into solid tumors by
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these hyperplastic islet nodules, while morphologically important test of the value of mouse models is the ap-
plicability of observations made therein to the humantransformed in appearance, are not competent to pro-
ceed directly to a rapidly growing islet cell carcinoma, condition. In two case studies, angiogenesis has been
detected in preneoplastic stages, consistent with identi-since 50% of the islets switch to the hyperproliferative
(CIS) stage, while only 1%–2% progress to solid tumors. fication of theangiogenic switch as a step in thepathway
to human cancer, as the following section elaborates.We have identified a discrete stage, referred to as “angi-
ogenic islet,” that appears to be an intermediate be-
tween these two stages, both statistically and tempo-
Angiogenesis in Premalignant Stagesrally. We defined the angiogenic switch using an in vitro
of Two Human Cancersbioassay for angiogenic activity, in which capillary endo-
The use of immunological markers to visualize the vas-thelial cells were cocultured in a three-dimensional col-
culature has become an important new tool in assessinglagen gel with islets isolated at different ages from the
the histopathology of cancerous lesions, as seen forRIP-Tag mice (Folkman et al., 1989). At early ages, none
example in the murine fibrosarcoma study discussedof the oncogene-expressing islets were angiogenic.
above (Kandel et al., 1991). Both von Willebrand’s factorThen, in older mice, individual islets scored as angio-
(vWF) and CD31 are expressed widely, albeit variably,genic, attracting a starburst of endothelial cells converg-
in the endothelium, which has allowed these and othering on the angiogenic islet. Over time, about 10% of the
markers to be used as tools to assess the density andtotal islets scored as angiogenic. The in vitro bioassay
character of capillaries in tissue sections. In human on-was substantiated by histological analysis, which re-
cology, an important application of this capability tovealed two hallmarks of angiogenesis, capillary sprout-
visualize capillaries has been the development of newing and endothelial cell proliferation, in a subset of the
prognostic tests for probability of relapse (or disease-hyperplastic islets and in all solid tumors in these
free survival) following surgical resection of an invasivetransgenic mice (Folkman et al., 1989). The provocative
cancer. Vessel density in invasive cancers has beenresult was that neither oncogene expression nor hyper-
demonstrated to be a significant prognostic indicator,proliferation appeared to be sufficient to activate the
both for breast (Weidner et al., 1991) and prostateangiogenic switch, which rather appeared as a discrete,
(Weidner et al., 1993) cancers; if the vessel density wastemporally separate step in this multistage pathway (Fig-
low, the prognosis was good, whereas the prognosisure 1A).
fell with increasing density of blood vessels, the mark ofA second transgenic mouse model of multistage tu-
a potent angiogenic response. In addition to evaluatingmorigenesis, in which the bovine papillomavirus onco-
malignant carcinomas, immunostaining with endothelialgenes elicit dermal fibrosarcomas (Lacey et al., 1986;
cell markers has been used to detect angiogenesis inSippola-Thiele et al., 1988), has also been analyzed for
preneoplastic lesions associated with cancers of thethe appearance of angiogenesis (Kandel et al., 1991).
mammary duct and the uterine cervix. The results areDense vascularization and evidence of new blood vessel
schematized in Figure 2. Briefly, histopathological evalu-growth first became apparent in a late preneoplastic
ation of biopsies taken from cancerous breasts has re-stage, aggressive fibromatosis; angiogenesis was also
vealed distinctive preneoplastic lesions, including hy-evident in all end-stage fibrosarcomas (Figure 1B). Even
perplastic ducts, dysplastic ducts, and CIS. Using vWFthough the fibrosarcoma model is very different from
immunostaining, a subset of the CIS lesions in the hu-the islet cell system, the results suggest again that angi-
man breast can be seen to be angiogenic (Brown et al.,ogenesis is a rate-limiting step in tumor development.
1995; Guidi et al., 1994; Weidner et al., 1992), in looseMoreover, the pattern persisted when a third transgenic
analogy to the subset of hyperproliferative (“CIS-like”)model was investigated, wherein basal keratinocytes
islets in the RIP-Tag mice that are angiogenic. In con-were progressively transformed into squamous cell car-
trast to the mouse, it has not been possible to performcinomas by the human papillomavirus type 16 onco-
comprehensive temporal and histological analyses ongenes (Arbeit et al., 1994, 1996; Arbeit, 1996; Coussens
the early development of these presumptive stages inet al., 1996; Hurlin et al., 1995). Here again, the angio-
the human breast, but the patterns are remarkably simi-genic switch was evident prior to the emergence of the
lar. Thus, we infer that angiogenic CIS lesions in thesquamous cancers (Figure 1C). In this multistage model
breast may represent an intermediate stage that sepa-of squamous carcinogenesis, weak angiogenic activity
rates preangiogenic CIS and invasive cancer.could be detected in the hyperplastic stage in the form
The human cervix has been extensively characterizedof modestly increased vessel density in the underlying
through the routine collection of PAP smears, whichdermis. Angiogenesis became pronounced in the dys-
has revealed a series of aberrant proliferative stages,plastic stage, with abundant capillaries juxtaposed to
ranging from varying grades of dysplasia to CIS (histo-the basement membrane separating stroma from dys-
logically graded as CIN I–III) and invasive cancer; aboutplastic cells. Intense vascularization persisted in the in-
80% of cervical carcinomas contain fragments of anvasive squamous cancers that arose out of such dys-
HPV genome (typically HPV16/18) and express viral on-plastic lesions (Smith-McCune et al., submitted).
cogenes. When biopsies of cervical lesions were ana-In summary, all three of the diverse transgenic mouse
lyzed by immunostaining with vWF to reveal the capillar-models of tumorigenesis analyzed to date have revealed
ies, an angiogenic switch was readily apparent in thean angiogenic switch that becomes activated during
mid–late dysplasias (CIN II–III), wherein new vessels be-the early stages of tumor development, suggesting that
came densely apposed along the basement membraneregulation of angiogenesis is a discrete, potentially rate-
limiting step in the pathway to many solid tumors. One underlying the dysplastic epithelium (Guidi et al., 1995;
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Figure 2. The Angiogenic Switch Can Be Visualized in Neoplastic Lesions Inferred to Be Progenitor Stages to Human Breast and Cervical
Cancer
(A) Breast cancers arise from the ductal epithelium of the breast; ductal lesions that are presumptive progenitors can be ordered into a
pathway of increasing aberrancy, beginning with hyperplasia and progressing to dysplasia and CIS. Of these, a subset of CIS lesions have
switched on angiogenesis, as evidenced by abundant new capillaries, suggesting that angiogenic-CIS is an intermediate stage between CIS
and invasive cancer.
(B) The squamous cervical epithelium evidences premalignant lesions graded as cervical intraepithelial neoplasia I–III, which are inferred to
represent a pathway to cervical cancer. A modest increase in new vessel density is evident in CIN I/II lesions, while CIN III lesions (analogous
to advanced dysplasia/CIS) show abundant new vessels, indicative of the angiogenic switch from vascular quiescence to sustained neovascu-
larization.
Smith-McCune and Weidner, 1994). An initial mild in- Therefore, having argued that regulation of the switch
crease in vessel density has been detected in the early is important and potentially rate-limiting for initial tumor
dysplastic (CIN I) stage (Guidi et al., 1995; Smith- development as well as for the expansion and metasta-
McCune et al., submitted). This pattern is remarkably sis of an established tumor, we now wish to discuss the
similar to that seen in the epidermis of K14–HPV16 emerging picture of how the angiogenic switch may be
transgenic mice, which presents a similar multistage controlled.
pathway in another squamous epithelium (of the skin)
under the influence of the HPV16 oncogenes. Thus, we
Emerging Mechanisms of the Angiogenic Switchinfer that the angiogenic switch is a very early event in
The Angiogenic Inducersthe pathways to invasive squamous cell cancers, per-
The observation that tumors could be implanted eitherhaps occurring in two regulatory phases, of mild and
into an avascular region, such as the cornea, or on aintense neovascularization. Clues from cell culture bio-
characteristically vascularized surface, such as theassays also support this notion that the switch can have
chick chorioalantoic membrane, and in each case elicitseveral “on” settings, which progressively ratchet up
the ingrowth of new capillaries, suggested that tumorsthe intensity of neovascularization.
released diffusible activators of angiogenesis that couldThe pattern of new blood vessel growth, described
signal a quiescent vasculature to begin capillary sprout-here in five cancers spanning two species and five cell
ing. This hypothesis motivated a search for so-calledtypes, argues, first, that the angiogenic switch is a dis-
tumor angiogenesis factors. Indeed, inducers of angio-crete process, subject to specific regulatory controls;
genesis have been identified. A number of in vitro andand second, that the switch is an essential part of the
in vivo bioassays have been developed to mimic thephenotypic repertoire that characterizes a successful
complex process of angiogenesis (reviewed by Cockerilltumor. Figure 3 presents a histological picture of the
et al., 1995). Among these, two assays in particular haveangiogenic switch in these five models. A similar stage-
been widely used to screen for angiogenic regulatoryspecificswitch is evident duringdevelopment of cutane-
ous melanoma in humans (reviewed by Rak et al., 1995). factors, each mimicking an aspect of angiogenesis;
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Figure 3. A Histological View of the Angio-
genic Switch
Tissue sections illustrate the situation before
and after the angiogenic switch in progenitor
lesions to tumors in the indicated tissues,
whose multistage developmental pathways
were summarized in Figures 1 and 2. In each
panel, the arrows highlight a few representa-
tive vessels in the quiescent (left column) or
angiogenic (right column) states. The top row
shows a hyperplastic mouse islet, full of pro-
liferating b cells (left), which contains a quies-
cent vasculature (as do normal islets), and
another islet nodule (right) that has switched
on new blood vessel growth (a few of which
are highlighted with arrows), with the hallmark
appearance of vascular lacuna (large arrow).
The human breast panels show a CIS (left),
with normal duct-associated vasculature,
and an angiogenic-CIS lesion (right), with ex-
tensive neovascularization. The mouse der-
mis panels show a prevascular mild fibro-
matosis lesion (left), with a few vessels deep
in the dermis, and an aggressive fibromatosis
(right), with large capillaries spread through-
out the thickened dermal layer. In the human
cervix, a normal tissue (left) has vessels deep
in the stroma, whereas the CIN III lesion (right)
has attracted a dense array of new capillaries
underlying the basement membrane. In the
normal mouse ear, a few vessels are present
in the stroma (left), whereas in HPV-16–
induced epidermal dysplasia, capillaries are
distributed throughout the dermis, in particu-
lar closely juxtaposed to the basement mem-
brane underlying the transformed keratino-
cytes. The islet panels were stained with
hematoxylin and eosin, while the remainder
were first immunostained with antisera to the
blood vessel marker vWF and then counter-
stained with hematoxylin alone or with hema-
toxylin and eosin (mouse dermis). All magnifi-
cations are approximately 623.
namely, endothelial cell proliferation and migration. The same time, a secreted protein was identified by its ability
to elicit vascular permeability (Senger et al., 1983); sub-proliferation assay uses cultured capillary endothelial
cells and measures either increased cell number or the sequently, this factor, called vascular permeability fac-
tor or vascular endothelial growth factor (VPF/VEGF),incorporation of radiolabeled or modified nucleosides
to detect cells in S phase. In contrast, the chemotaxis was shown to be a potent inducer of angiogenesis (re-
viewed by Brown et al., 1996; Ferrara, 1993). Recently,assay separates endothelial cells and a test solution by
a porous membrane disc (a Boyden Chamber), such two related endothelial growth factors, VEGF-B and
VEGF-C, have been identified (Olofsson et al., 1996;that migration of endothelial cells across the barrier is
indicative of a chemoattractant present in the test solu- Joukov et al., 1996; Lee et al., 1996; Grimmond et al.,
1996). All three VEGF genes as well as acidic and basiction. Both assays have inherent strengths, biases, and
limitations; each is often complemented by the use of FGF are widely expressed in normal adult organs of
mice and humans, suggestive of roles in tissue homeo-an in vivo assay, such as implants into the normally
avascular cornea of rabbits or rodents (the “corneal stasis as well as angiogenesis, since the later is such a
rare event in most tissues. Both a/bFGF and VEGF bindpocket” assay). A number of inducers of angiogenesis
have been detected using these assays. The first to be to receptorson endothelial cells that are transmembrane
tyrosine kinases and thus arecoupled through the signaldiscovered (in 1982) was basic fibroblast growth factor
(bFGF, or FGF-2), followed shortly by its relative, acidic transduction cascade to the cellular regulatory network.
The three VEGF receptors, flk, flt-1, and flt-4 (VEGFR-FGF (aFGF, or FGF-1; reviewed by Christofori, 1996;
Friesel and Maciag, 1995; Folkman and Shing, 1992). 1–3), are specifically expressed on endothelial cells (re-
viewed by Brown et al., 1996; Risau and Flamme, 1995),Both proteins are members of a family of growth factors
that are characterized by high affinity binding to heparin; whereas the four FGF receptors, FGFR1–4, are more
widely expressed (reviewed by Christofori, 1996; Frieseleach is unusual in its lack of a traditional signal sequence
for secretion. Both, however, can be released from cells and Maciag, 1995; Rak et al., 1995).
During the past decade, an increasing number of angi-under certain circumstances (Christofori, 1996; Friesel
and Maciag, 1995; Kandel et al., 1991). At about the ogenic inducers has been identified (reviewed by Bouck
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et al., 1996; Folkman, 1995a, 1995b). Concurrently, how- as astrocytes (Van Meir et al., 1994), to controlangiogen-
esis-inhibitory activities distinct from TSP. The bottomever, a pattern has emerged, in that bFGF and VEGF
are commonly expressed in a wide variety of human line of these experiments is, first, that endogenous angi-
ogenesis inhibitors can serve to counteract inducer sig-and animal cancers; moreover, bFGF (and now VEGF)
is being detected at elevated levels in the urine and nals to grow new capillaries; and second, that these
angiogenesis inhibitors can be controlled by tumor sup-serum of a significant fraction of tumor-bearing patients
(as discussed in Folkman, 1995a, 1995b). Interestingly, pressor genes, consistent with the functional definition
of such genes as interfering with the tumor phenotype,VEGF and bFGF have been shown to synergize using
in vitro angiogenesis assays (Pepper et al., 1992; Goto et of which angiogenesis is a key component.
A New Paradigm of Cryptic Angiogenesisal., 1993), indicating that they can serve complementary
functions, consistent with their common association in Inhibitors within Larger Proteins
The fact that the endothelium is quiescent for long peri-tumors. Indeed, the tumor development pathways of all
three transgenic mouse models presented in Figure 1 ods and yet can be induced to sprout new capillaries
in a matter of hours in response to, for example, aevidence an involvement of VEGF and either aFGF,
bFGF, or both. Thus, these two classes of angiogenic wound, has long suggested that angiogenesis regula-
tors might be stored for expedient use. In addition, oneinducer certainly represent a frequent component of the
angiogenic switch. Notwithstanding this consensus, the can expect that regulators will be synthesized for persis-
tence of an angiogenic response. It is known that thediversity and number of angiogenic inducers identified
to date argues that there will also prove to be tissue- FGFs and other growth and angiogenic factors can be
sequestered in the extracellular matrix of many cellspecific and perhaps transformation-specific regulators
associated with particular cancers and with the normal types, including endothelial cells, presumably to be re-
leased by proteolytic degradation of the matrix (Bairdphysiological regulation of angiogenesis. Moreover,
convergent on this perspective regarding angiogenic and Ling, 1987; Folkman et al., 1988). It now appears
that angiogenesis inhibitors are also stored, but in ainducers has been the realization that there is an equally
important component to the switch, one governed by much different fashion, as cryptic parts of larger mole-
cules that are not themselves inhibitors of angiogenesis.negative regulatory factors, called angiogenesis inhib-
itors. The prototype came from the discovery that a 29 kDa
fragment of fibronectin inhibited endothelial cell prolifer-The Angiogenic Inhibitors
The firstclues to the existenceof endogenous angiogen- ation in vitro (Homandberg et al., 1985). Notably, the
intact fibronectin molecule, an abundant component ofesis inhibitors came with the observations that a inter-
feron (Brouty-Boye and Zetter, 1980; Sidky and Borden, the circulatory system, was not itself an inhibitor. Subse-
quently, a fragment of prolactin, the 16 kDa fragment,1987) and platelet factor-4 (Taylor and Folkman, 1982;
Sato et al., 1990; Sharp et al., 1990) could inhibit endo- was shown to be an inhibitor of endothelial cells,
whereas the intact molecule was not (Clapp et al., 1993;thelial cell chemotaxis and proliferation, respectively.
But the significance of negative regulators of angiogen- Ferrera et al., 1991). More recently, a potent inhibitor of
angiogenesis, called angiostatin, has been identified asesis first became apparent through a series of experi-
ments by Bouck and colleagues (Good et al., 1990; Ras- a fragment of plasminogen (O’Reilly et al., 1994). Circu-
lating angiostatin is able to maintain the dormancy oftinejad et al., 1989). A nontumorigenic hamster cell line
became tumorigenic concomitant with a mutation that metastases and primary tumors by blocking blood ves-
sel growth, resulting in small nests of tumor cells thatinactivated a tumor suppressor gene. Comparison of
cell lines containing or missing the suppressor gene cycle through proliferation and apoptosis, restrained by
their inability to induce angiogenesis to support theirrevealed that the nontumorigenic line released high lev-
els of a potent angiogenesis inhibitor, bothof endothelial growth (Holmgrenet al., 1995; O’Reilly et al., 1994, 1996).
The fact that abundant components of the circulatorychemotaxis in the Boyden Chamber assay and of in vivo
neovascularization using the corneal pocket assay; by system such as fibronectin and plasminogen can be
converted into potent angiogenic factors suggests acomparison, the tumorigenic cell lines had much lower
levels of inhibitor (Rastinejad et al., 1989). The inhibitory new form of regulation, whereby proteases specifically
release 29 kDa fibronectinor angiostatin from their intactactivity was purified and shown to be a truncated form
of thrombospondin-1 (TSP-1), a secreted glycoprotein. parental molecules to limit an angiogenic response, for
example in the transient wound healing process. Re-Subsequently, the intact TSP-1 molecule was shown to
be an angiogenesis inhibitor (Good et al., 1990), as were cently, platelet factor-4, itself a weak angiogenesis in-
hibitor, has been shown to contain a fragment that issmall peptides contained within it (Tolsma et al., 1993).
Further, TSP-1 has been shown to be expressed at high 50 times more potent at inhibiting angiogenesis (Gupta
et al., 1995). The pattern of protease fragments as angio-levels in a number of normal rodent and human cells
and at appreciably lower levels in many tumor cells. genesis inhibitors continues to expand to other mole-
cules, including the propeptides of type 1 collagen (Tol-Provocatively, TSP-1 has recently been shown to be
regulated by the wild-type p53 tumor suppressor protein sma et al., 1993) and a peptide fragment of epidermal
growth factor (Nelson et al., 1995).in fibroblasts (Dameron et al., 1994) and mammary epi-
thelial cells (Volpert et al., 1995), such that upon loss of Thus, a paradigm is emerging which suggests that a
class of angiogenesis inhibitors is contained within otherp53 function in their transformed derivatives, the levels
of this angiogenesis inhibitor dropped precipitously. proteins that are not themselves inhibitors. The capabil-
ity to release inhibitor fragments from storage as crypticRestoration of p53 function upregulated TSP-1 and im-
paired the angiogenic capability of the tumor cells. Fur- segments of abundant proteins may contribute to main-
taining the normal quiescence of the vasculature andthermore, p53 has been shown in other cell types, such
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Figure 4. The Balance Hypothesis for the Angiogenic Switch
The normally quiescent vasculature can be activated to sprout new capillaries (angiogenesis), a morphogenic process controlled by an
angiogenic switch mechanism. The prevailing evidence suggests that changes in the relative balance of inducers and inhibitors of angiogenesis
can activate the switch. In some tissues, the absence of angiogenesis inducers may keep the switch off, while in others the angiogenesis
inducers are present but held in check by higher levels of angiogenesis inhibitors. Thus, either reducing the inhibitor concentration, e.g., for
TSP-1, by loss of a tumor suppressor gene; or increasing the activator levels, e.g., for induction of VEGF, by hypoxia, can each change the
balance and activate the switch, leading to the growth of new blood vessels.
to turning off transitory angiogenic processes such as 1989). The second clue comes from studying human
tumor cells, in which the restoration of p53 tumor sup-ovulation and wound healing; perhaps this strategy also
serves the organism by suppressing tumorigenesis and pressor function results in up-regulation of TSP, overrul-
ing both the angiogenesis inducers that the cells them-other diseases with an angiogenic component. A major
question for the future relates to the source and regula- selves synthesize as well as added bFGF, thereby
blocking angiogenesis (Dameron et al., 1994). The thirdtion of the proteases that release the cryptic inhibitors.
In one case, that of angiostatin, certain clones of Lewis clue comes fromthe pancreatic islet model for theangio-
genic switch (see Figure 1), in which two potent angio-lung tumor paradoxically induce its release from circu-
lating plasminogen (O’Reilly et al., 1994). Beyond that, genic factors, aFGF and VEGF, are expressed consitu-
tively in normal islet cells (of nontransgenic mice) asit is not clear what cell types normally serve to release
cryptic inhibitors and under what circumstances. Eluci- well as throughout tumorigenesis in the transgenic mice
(Christofori, 1996; Christofori et al., 1995b). Remarkably,dation of mechanisms and regulation of cryptic angio-
genic inhibitor release could well present therapeutic there is nonew bloodvessel growth innormal pancreatic
islets, despite the expression of these potent angiogen-opportunities.
The Balance Hypothesis for the Angiogenic Switch esis inducers. It seems likely that angiogenesis inhibitors
keep the switch off in normal islets expressing VEGFThe above sections have summarized the evidence that
angiogenesis can be regulated both by inducers and and aFGF. If so, then loss of these inhibitors would shift
the balance and trigger the switch during tumorigenesis.inhibitors of endothelial cell proliferation and migration.
But which class of angiogenic regulators is most impor- Indeed, genetic evidence exists for an angiogenesis
suppressor gene located on mouse chromosome 16;tant? Increasingly, there are provocative clues sug-
gesting that the balance of inhibitors and inducers this locus frequently shows loss of heterozygosity both
in the angiogenic islet stage and in end-stage tumorsgoverns the angiogenic switch; the hypothesis is sche-
matized in Figure 4. A set of three clues summarizes of this tumorigenesis pathway (Parangi et al., 1995). The
predictions are, therefore, first, that an angiogenesisthe basis for this hypothesis. The first clue comes from
in vitro bioassays. In both proliferation and chemotaxis suppressor gene encodes or controls expression of an
angiogenesis inhibitor that maintains the quiescence ofassays, bFGF and VEGF can elicit a positive response
from capillary endothelial cells. If increasing amounts the vasculature innormal islets constitutivelyexpressing
VEGF and aFGF; and second, that this angiogenic inhibi-of an inhibitor such as TSP-1 are added, the response
becomes blocked, suggesting that when the levels of tor is down-modulated during tumorigenesis, thus acti-
vating the angiogenic switch.inhibitors are sufficiently high, the signals of the positive
activator(s) are overruled, keeping (or turning) the angio- These and other clues suggest a regulatory mecha-
nism that integrates the cumulative levels of inducergenic switch off (Good et al., 1990; Rastinejad et al.,
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and inhibitor signals to maintain the endothelial cell in Apoptosis, Clinical Applications, and the Goal
to Control the Switchalternative states of quiescence or angiogenesis. Thus,
The growing appreciation of the fact that angiogenesischanges in the balance of positive and negative signals
is an integral component of the tumor phenotype hasmediate the angiogenic switch (Figure 4), a point Bouck
fueled considerable efforts to identify angiogenesis in-and colleagues have also made recently (Bouck et al.,
hibitors that can be used as part of therapeutic strate-1996). A net balance of inhibitors over activators would
gies to interfere with tumor growth and metastasis. Inmaintain the switch in the off position, whereas a shift
addition to endogenous inhibitors such as interferon a/bto an excess of activating stimuli would turn on angio-
and platelet factor-4, synthetic compounds have beengenesis. There are now ample tools to address this hy-
identified using cell culture assays. These include thepothesis, and indeed, new observations seem likely to
fungal-derived compound AGM1470 (TNP470), thalido-refine it. For example, aFGF and bFGF are selectively
mide, a number of metalloproteinase inhibitors, and oth-exported by a number of tumor cell lines but not by
ers (reviewed by Auerbach and Auerbach, 1994; Bouckmany normal cells (Christofori, 1996; Friesel and Maciag,
et al., 1996; Folkman, 1995a). Currently, there are nine1995; Kandel et al., 1991), suggesting that another fea-
compounds in clinical trials as angiogenesis inhibitors,ture of the switch mechanism may be the capability
with perhaps two dozen others in various stages of re-to sequester angiogenesis inducers such that despite
search and development as potential antiangiogenic
being synthesized they are unavailable to stimulate angi-
therapeutics.
ogenesis until the sequestration is relaxed. In regard to
Looking beyond this first generation of angiogenesis
endogenous inhibitors, a major objective will be to as-
inhibitors identified in cell-based assays, we envision
sess the proteolytic mechanisms and the generality by the capability to control the angiogenic switch through
which cells can process abundant circulatory proteins specific knowledge both of the regulatory mechanism
such as fibrinogen and plasminogen to release cryptic underlying the switch and the cellular details of the pro-
angiogenesis inhibitors. Local processing of circulatory cess of new blood vessel morphogenesis. Oneapproach
proteins may serve to produce levels of inhibitory activ- will likely involve altering the balance of endogenous
ity sufficient to maintain the angiogenic switch in the off inhibitors and activators by controlling synthesis or af-
position. If the endothelium is normally bathed in locally fecting sequestration and release. The beginnings of
or systemically processed cryptic inhibitors, the regula- this approach are apparent. Monoclonal antibodies that
tory balance could be shifted and the angiogenic switch bind and block the actions of VEGF are in development,
activated either by reducing the rates of inhibitor pro- as are compounds that interfere with signal transduction
cessing or by increasing the levels of the inducers seen from its receptors. Knowledge of the morphogenesis of
at the endothelial cell, for example by up-regulating new vessels is also providing opportunities. For exam-
VEGF synthesis or by releasing sequestered FGF. It ple, sprouting capillaries have been shown to express
seems likely that the alternative strategies of increasing a specific type of cell–matrix interaction molecule, the
activator levels or reducing inhibitor levels to activate integrins avb3 or avb5; abrogation of the contacts of these
the angiogenic switch will each be utilized by different integrins to matrix evokes programmed cell death
(apoptosis) of the new endothelial cells and dramaticallytissues according to their physiological characteristics.
impairs neovascularization of tumors (Brooks et al.,Thus, tissues such as the epidermis, which are well
1994; Friedlander et al., 1995). Both antiintegrin antibod-separated from the vasculature by a basement mem-
ies and interfering RDG peptides are in developmentbrane and a stromal support, may favor mechanisms
as candidates for blocking capillary morphogenesis viathat increase inducer levels to elicit angiogenesis. In
induction of apoptosis.contrast, endocrine organs such as the pancreatic islets
One emerging biological principle is the interrelation-that are intimately vascularized may utilize negative reg-
ship between tumor angiogenesis and modulation ofulators to maintain a quiescent endothelium and there-
cell death. Classically, it has been apparent in certainfore require down-regulation of inhibitor production to
tumors that necrotic death accompanies inadequateactivate the angiogenic switch.
blood flow; for example, necrosis has been reported inThe realization that increasing numbers of both angio-
glioblastomas and attributed to hypoxia resulting fromgenic activators and inhibitors are being discovered
inadequate vascularization. In turn, this clue led to the
(currently, there are at least a dozen of each), most
discovery that hypoxia can induce VEGF synthesis
with demonstrable activity directly on endothelial cells,
(Shweike et al., 1992; Shweiki et al., 1995; Stein et al.,
raises an interesting question: how are all of these com- 1995). One study in which VEGF receptor function was
plementary and opposing signals integrated by the sig- inhibited in a transplantable glioblastoma with a domi-
nal transduction network in endothelial cells, so as to nant-negative VEGF receptor resulted in impaired tumor
control the complex dynamics of maintaining quies- growth, which was ascribed to widespread necrotic cell
cence, activating angiogenesis, and then completing death (Millauer et al., 1994). In addition, however, to
differentiation to produce functional new capillaries? necrotic cell death, it is now becoming clear that rapid
Beyond the manifest goal of further clarifying the regula- expansion of a tumor mass can be significantly affected
tory mechanisms of the angiogenic switch and the com- by the incidence of apoptosis.
plex process of angiogenesis, an important opportunity To exemplify the interplay of apoptosis and angiogen-
now exists to apply this new knowledge in clinical oncol- esis, consider the transplantable Lewis lung carcinoma
ogy to restrict angiogenesis by altering the balance of model (Figure 5A). Lewis lung tumors growing subcuta-
neously in mice seed distant metastases in the lung, butangiogenic regulators.
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Figure 5. Tumor Growth Can Be Restricted by Apoptosis of Tumor Cells Elicited by Inhibition of Angiogenesis
(A) Liver metastases from a subcutaneous growth of Lewis lung carcinoma will grow explosively in the absence (i) of the primary tumor, which
produces a circulating endothelial inhibitor (angiostatin). The apoptotic index is low and the proliferation index very high. When the primary
tumor is present (ii), resulting in high serum levels of angiostatin, growth of the metastases is impaired, and the apoptotic index is markedly
increased in the metastatic nodules. If the primary tumor generating angiostatin is absent, but instead the angiogenesis inhibitory drug
AGM1470 (TNP470) is inoculated daily (iii), metastatic growth is again restricted, concomitant with increased apoptosis. Neither angiogenesis
inhibitor affects the proliferation index of the metastatic tumor cells (shown); in both cases, the density of new capillaries is significantly
reduced (data not shown).
(B) Transgenic mice expressing the SV-Tag oncogene in pancreatic b cells develop islet cell carcinomas with a high proliferation index and
a low incidence of apoptosis (i). In the absence of the survival factor IGF-II, tumor volume is dramatically impaired, with a concordant 53
increase in apoptotic index (ii), demonstrating that apoptosis can restrain primary tumor growth. When the transgenic mice are treated with
a regimen of angiogenesis inhibitors, including AGM1470, tumor growth is again impaired, also with a concordant increase in the incidence
of apoptosis (iii), indicating that the reduced vascularization (data not shown) elicits tumor cell apoptosis. Again, tumor cell proliferation is
not affected by inhibition of angiogenesis.
these remain dormant as small nodules of tumor cells and two additional murine tumors in immunodeficient
and syngeneic mice, respectively; tumors in the angios-that do not elicit angiogenesis, as a consequence of the
presence in the blood of high levels of the angiogenesis tatin-treated mice also had comparable proliferation in-
dices to saline-treated controls and markedly increasedinhibitor angiostatin, which is released from circulating
plasminogen by the primary tumor (O’Reilly et al., 1994.) frequencies of tumor cell apoptosis (O’Reilly et al., 1996).
In a second example, that of islet cell carcinomas(The reason that angiostatin does not inhibit angiogen-
esis in the primary tumor is not clear but is thought to in RIP-Tag transgenic mice (Figure 1A), the end-stage
tumors evidence a low incidence of apoptosis, whichreflect a local balance in favor of angiogenesis inducers.)
Examination of the latent metastases revealed a high appears to be maintained both by intrinsic factors and
by intense vascularization of tumors (Figure 5B). Whenincidence of S-phase cells (30%) and yet little increase
in metastatic tumor mass. The explanation appears to the embryonic growth/survival factor IGF-II, which is
activated in this tumorigenesis pathway, was abrogatedbe that the latent metastases evidence a high incidence
of apoptosis (8%), balancing rapid cell division with cell using gene-knockout mice, the tumor volume was dra-
matically decreased (Christofori et al., 1994, 1995a; Naikdeath (Holmgren et al., 1995). Release of the angiogenic
blockade (by removing the primary tumor) allowed angi- et al., 1994). The S-phase incidence was comparably
high (more than 20%) in both normal and IGF-II–deficientogenesis and rapid expansion of lung metastases (Hol-
mgren et al., 1995; O’Reilly et al., 1994). The synthetic tumors (Naik et al., 1994); the difference was in theapop-
totic incidence, which rose 5-fold in the IGF-II–null tu-angiogenesis inhibitor AGM1470 could similarly hold la-
tent metastases in place; again, the pattern was one of mors (Christofori et al., 1994). Thus, IGF-II produced by
the tumor cells is implicated in the control of apoptosis.high incidence both of cells in S phase and of cells
undergoing apoptosis (Holmgren et al., 1995). Recently, Yet the low level of apoptosis seen in the islet cell tumors
is also highly dependent on persistent angiogenesis.purified angiostatin has been shown to impair signifi-
cantly the growth of three primary human carcinomas When the RIP-Tag mice were treated with a regimen of
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